TY  - JOUR
AU  - Jaramillo, S.
AU  - Benner, A.
AU  - Krauter, J.
AU  - Martin, H.
AU  - Kindler, T.
AU  - Bentz, M.
AU  - Salih, H. R.
AU  - Held, G.
AU  - Köhne, C-H
AU  - Götze, K.
AU  - Lübbert, M.
AU  - Kündgen, A.
AU  - Brossart, P.
AU  - Wattad, M.
AU  - Salwender, H.
AU  - Hertenstein, B.
AU  - Nachbaur, D.
AU  - Wulf, G.
AU  - Horst, H-A
AU  - Kirchen, H.
AU  - Fiedler, W.
AU  - Raghavachar, A.
AU  - Russ, G.
AU  - Kremers, S.
AU  - Koller, E.
AU  - Runde, V.
AU  - Heil, G.
AU  - Weber, D.
AU  - Göhring, G.
AU  - Döhner, K.
AU  - Ganser, A.
AU  - Döhner, H.
AU  - Schlenk, Richard
TI  - Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.
JO  - Blood cancer journal
VL  - 7
IS  - 5
SN  - 2044-5385
CY  - London [u.a.]
PB  - Nature Publishing Group
M1  - DKFZ-2017-01183
SP  - e564 -
PY  - 2017
AB  - The aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given on days 1, 3 and 5 (HDAC-135) as well as to evaluate the prophylactic use of pegfilgrastim after chemotherapy in younger patients with acute myeloid leukemia in first complete remission. One hundred and seventy-six patients were treated with HDAC-135 and 392 patients with HDAC-123 with prophylactic pegfilgrastim at days 10 and 8, respectively, in the AMLSG 07-04 and the German AML Intergroup protocol. Time from start to chemotherapy until hematologic recovery with white blood cells >1.0 G/l and neutrophils >0.5 G/l was in median 4 days shorter in patients receiving HDAC-123 compared with HDAC-135 (P<0.0001, each), and further reduced by 2 days (P<0.0001) by pegfilgrastim. Rates of infections were reduced by HDAC-123 (P<0.0001) and pegfilgrastim (P=0.002). Days in hospital and platelet transfusions were significantly reduced by HDAC-123 compared with HDAC-135. Survival was neither affected by HDAC-123 versus HDAC-135 nor by pegfilgrastim. In conclusion, consolidation therapy with HDAC-123 leads to faster hematologic recovery and less infections, platelet transfusions as well as days in hospital without affecting survival.
LB  - PUB:(DE-HGF)16
C6  - pmid:28548643
DO  - DOI:10.1038/bcj.2017.45
UR  - https://inrepo02.dkfz.de/record/124287
ER  -